ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

Item5.02.Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On May 22, 2017, Actinium Pharmaceuticals, Inc (the Company)
entered into a three month consulting agreement (the Consulting
Agreement) with Dr. Cicic to which he will be paid consulting
fees at the same rate of pay as his current salary prior his
resignation as Chief Technology Officer. A copy of the Consulting
Agreement will be included as an exhibit to the Companys Form
10-Q for the quarter ending June 30, 2017.


About ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM)

Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) Recent Trading Information

ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) closed its last trading session 00.00 at 1.41 with 200,055 shares trading hands.

An ad to help with our costs